A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies

J Hematother Stem Cell Res. 2002 Feb;11(1):33-47. doi: 10.1089/152581602753448522.


Tumor angiogenesis is currently not only a concept but has also become a rationale for the therapeutic use of both old and new drugs that might affect new blood vessel formation. There is growing evidence that angiogenesis is as important in hematologic malignancies as it is in solid tumors. Both myeloid and lymphoid disorders may be accompanied by a prognostically detrimental increase in bone marrow microvessel density. In this review, we summarize the current literature as well as our own studies regarding bone marrow angiogenesis and the use of anti-angiogenic treatment in hematologic disorders. Background information on pathogenesis and laboratory methods of quantifying bone marrow angiogenesis is also discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Bone Marrow / blood supply
  • Bone Marrow / pathology
  • Bone Marrow / physiopathology
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Hematologic Neoplasms / physiopathology
  • Humans
  • Neovascularization, Pathologic / diagnosis
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / prevention & control


  • Angiogenesis Inhibitors